SCHEMBL7247232

SCHEMBL7247232

c1ccc(CN[C@H]2CCCC[C@@H]2Cc2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.52
ADRA2B P18089 1/20 0.52
ADRA2C P18825 1/20 0.52
KDM1A O60341 3/20 0.49
MAOA P21397 1/20 0.49
LTA4H P09960 2/20 0.45
GRIN2B Q13224 2/20 0.45
FUCA1 P04066 1/20 0.43
BCHE P06276 2/20 0.41
ACHE P22303 2/20 0.41
BACE1 P56817 2/20 0.41
MME P08473 1/20 0.41
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
SSTR3 P32745 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7177046 1.00 ADRA2A (0.52) ADRA2AADRA2BADRA2CKDM1AMAOA
SCHEMBL7247234 1.00 ADRA2A (0.52) ADRA2AADRA2BADRA2CKDM1AMAOA
SCHEMBL2197644 0.85 KDM1A (0.58) KDM1AMAOAGRIN2BFUCA1BCHE
SCHEMBL2936924 0.85 KDM1A (0.58) KDM1AMAOAGRIN2BFUCA1BCHE
SCHEMBL491107 0.85 KDM1A (0.58) KDM1AMAOAGRIN2BFUCA1BCHE
SCHEMBL2198525 0.85 KDM1A (0.58) KDM1AMAOAGRIN2BFUCA1BCHE
SCHEMBL2798417 0.85 KDM1A (0.58) KDM1AMAOAGRIN2BFUCA1BCHE
SCHEMBL2197651 0.85 KDM1A (0.58) KDM1AMAOAGRIN2BFUCA1BCHE
SCHEMBL13636960 0.85 KDM1A (0.47) KDM1AMAOALTA4HGRIN2BFUCA1
SCHEMBL249579 0.85 LTA4H (0.60) KDM1AMAOALTA4HGRIN2BFUCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030191279-A1 Urea derivatives useful as anticancer agents GOLDSTEIN STEVEN WAYNE (US) 2003-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191279-A1 Urea derivatives useful as anticancer agents CCNA1, CCNE1, CCND1 ADRA2A 4469/4885ADRA2B 4009/4885ADRA2C 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.